Innate Pharma S.A. IPHA
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -55.36M | -56.06M | -55.81M | -52.78M | -50.09M |
| Total Depreciation and Amortization | 1.50M | 1.55M | 1.56M | 1.62M | 1.70M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1.41M | 3.95M | 6.35M | 5.90M | 5.46M |
| Change in Net Operating Assets | 2.71M | -4.62M | -11.37M | -6.73M | -1.90M |
| Cash from Operations | -49.74M | -55.18M | -59.27M | -52.00M | -44.84M |
| Capital Expenditure | -200.60K | -181.20K | -159.00K | -168.90K | -180.40K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 2.94M | 5.69M | 8.15M | 12.39M | 16.76M |
| Cash from Investing | 2.74M | 5.51M | 7.99M | 12.22M | 16.58M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -6.82M | -7.87M | -8.91M | -8.94M | -8.97M |
| Issuance of Common Stock | 49.00K | 7.52M | 14.98M | 16.37M | 17.77M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -7.90M | -578.30K | 6.32M | 7.99M | 9.64M |
| Foreign Exchange rate Adjustments | -213.50K | 513.50K | 1.20M | 1.03M | 849.10K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -55.11M | -49.74M | -43.76M | -30.77M | -17.77M |